Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
Top Cited Papers
- 1 November 2004
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 127 (5), 1347-1355
- https://doi.org/10.1053/j.gastro.2004.08.002
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061Journal of Virology, 2004
- 136 Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1Hepatology, 2003
- Natural history of chronic hepatitis CHepatology, 2002
- Optimal therapy of hepatitis CHepatology, 2002
- Use and interpretation of virological tests for hepatitis CHepatology, 2002
- Hepatitis C advances in antiviral therapy: What is accepted treatment now?Journal of Gastroenterology and Hepatology, 2002
- Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trialsGastroenterology, 1999
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell LineScience, 1999
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998